Corcept’s CATALYST clinical trial assessed the prevalence of hypercortisolism in patients with difficult-to-control Type 2 diabetes. The results demonstrated a prevalence rate of 24 percent. The trial enrolled 1,055 patients across 36 sites in the U.S., making it the largest and most rigorous study ever conducted assessing prevalence in this population. Read more here.

Watch the presentation at the American Diabetes Association’s 84th Scientific Sessions featured plenary session here: